Subscribe

AVBCC 2013 3rd Annual Conference Abstracts

Background:  Clinical pathways have been in existence since the 1980s1  to guide treatment of oncology patients based on established treatment evidence. Despite their tenure in the healthcare space, there is still much debate over the implementation and use of clinical pathways in medical practices. Faced with rising healthcare costs, payers have begun to show a greater interest in clinical pathways as a utilization management tool and as a way to control costs.

Background: Clinical pathways are a growing payer management technique for controlling costs and standardizing care. Their use in other therapeutic areas has helped payers control costs and standardize care; however, use of pathways in oncology has not been assessed.
Objective: To determine trends in payer use of pathways in management of oncology therapies and to identify specific tumor types that are current and future focuses in pathway design.

Background: Denosumab and zoledronic acid (ZDA) are used in the management of bone metastases and osteopenia secondary to hormonal therapy in patients with cancer. Study results range from suggesting similar efficacy between the two agents to possible superiority of denosumab in certain populations.

Background: Radiation therapy is considered the main line of treatment after resection of brain metastases, atypical meningioma or primary brain tumors. Different techniques are used for radiation therapy, including intensity-modulated radiation therapy (IMRT) and stereotactic radiosurgery (SRS). The use of SRS in patients with brain metastases increased significantly especially with conflicting data about the survival benefit of whole brain radiation (WBRT).

Background: Advanced colorectal cancer treatment options are evolving with a multitude of chemotherapeutic agents, biologics (both epidermal growth factor receptor inhibitors and anti-angiogenic agents), and a newly approved tyrosine kinase inhibitor available to treat metastatic colorectal cancer (mCRC) patients.

Abstracts to Be Presented at the
 Third Annual Conference of the Association for Value-Based Cancer Care

May 2-5, 2013
Westin Diplomat, Hollywood, FL

 

Category: Cost-Effectiveness Analysis

Page 3 of 3
Results 21 - 26 of 26
  • Rheumatology Practice Management
  • American Health & Drug Benefits
  • Value-Based Cancer Care
  • Value-Based Care in Myeloma
  • Value-Based Care in Neurology